> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# USC Scholar Proposes Conditional Drug Approvals Based on Phase 2 Trials
- URL: https://www.fdaweb.com/usc-scholar-proposes-conditional-fda-drug-approvals-based-on-phase-2-trials/
- Published: 2026-11-19T20:09:13.000Z
- Updated: 2026-11-19T20:20:06.000Z
- Author: David McFarland
- Tags: Drugs

FDA should consider allowing certain investigational drugs onto the market following successful randomized Phase 2 trials, subject to completion of confirmatory studies, according to a proposal by University of Southern California health economist **Neeraj Sood**.

Writing in an 11/19 [Washington Post opinion article](https://www.washingtonpost.com/opinions/2026/11/19/fda-drug-trials-can-be-reformed-without-sacrificing-safety/?ref=fdaweb.com), Sood, a senior scholar at USC's Schaeffer Institute, argues that FDA's approval framework should account for the potential harm caused by delaying access to effective treatments, as well as the risks of approving unsafe or ineffective drugs.

Under his proposed time-limited conditional approval pathway, drugs demonstrating meaningful patient benefits and acceptable safety in randomized Phase 2 trials could become available while larger confirmatory studies proceed. Continued marketing would depend on subsequent evidence establishing that benefits outweigh risks.

Unlike FDA's existing accelerated approval pathway, which frequently relies on surrogate endpoints, Sood's proposal would require randomized evidence of actual clinical benefit.

Sood acknowledges that some conditionally approved drugs might subsequently fail confirmatory testing or reveal unexpected risks. He advocates stronger postmarketing safety surveillance to accompany earlier patient access.